Table 3.
Univariate and multivariate analyses of the prognostic risk factors for overall survival in PTCL
| Variable | Univariate analysis
|
Multivariate analysis
|
||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| ECOG (0–1 vs 2–4) | 1.84 (0.25–3.56) | 0.031 | 1.38 (0.82–3.15) | 0.635 |
| Ann Arbor stage (I–II vs III–IV) | 1.24 (1.35–4.67) | 0.134 | ||
| B symptoms (absent vs present) | 2.57 (0.45–7.89) | 0.032 | 0.82 (0.34–2.18) | 0.514 |
| β2-MG (normal vs elevated) | 0.73 (0.46–3.24) | 0.572 | ||
| LDH (normal vs elevated) | 0.59 (0.14–2.31) | 0.786 | ||
| IPI (1–2 vs 3–5) | 4.12 (1.59–6.45) | 0.028 | 4.12 (1.36–6.72) | 0.01 |
| CCI (0–1 vs ≥2) | 3.24 (0.73–6.45) | 0.019 | 3.56 (0.82–4.51) | 0.006 |
| Therapeutic evaluation (CR/PR vs SD/PD) | 2.38 (0.62–6.42) | 0.673 | ||
Abbreviations: PTCL, peripheral T-cell lymphoma; HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; β2-MG, β-microglobulin; LDH, lactate dehydrogenase; IPI, International Prognostic Index; CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease; CCI, Charlson Comorbidity Index Score.